Summary of Abaxis, Inc. (NASDAQ:ABAX) Ratings

June 29, 2018 - By Madeline Delgado

Abaxis, Inc. (NASDAQ:ABAX) Corporate Logo
During Q1 2018 the big money sentiment increased to 1.48. That’s change of 0.21, from 2017Q4’s 1.27. 11 investors sold all, 45 reduced holdings as Abaxis, Inc. ratio increased. 46 increased stakes while 37 funds took stakes. Funds hold 20.94 million shares thus 3.32% less from 2017Q4’s 21.66 million shares.
Manufacturers Life Ins Com The reported 16,751 shs. 15,287 were reported by Thrivent Fin For Lutherans. Peak6 Limited Partnership has invested 0% of its capital in Abaxis, Inc. (NASDAQ:ABAX). Prudential Financial Incorporated has invested 0% of its capital in Abaxis, Inc. (NASDAQ:ABAX). Paradigm Asset Mngmt Limited Com accumulated 1,350 shs or 0% of the stock. Wells Fargo Commerce Mn has invested 0.01% of its capital in Abaxis, Inc. (NASDAQ:ABAX). 16,045 are held by State Of Tennessee Treasury Department. C M Bidwell Assocs holds 0.01% or 102 shs. 5,268 are held by Citigroup. Swiss Fincl Bank, a Switzerland-based fund reported 39,500 shs. Hl Finance Service Ltd Liability Company invested in 4,725 shs. Secor Capital Advsrs L P owns 8,054 shs. Point72 Asset Mgmt L P invested in 0% or 10,600 shs. Mason Street Advsr Llc has invested 0.01% in Abaxis, Inc. (NASDAQ:ABAX). Pinebridge L P holds 0.04% of its capital in Abaxis, Inc. (NASDAQ:ABAX) for 24,584 shs.

Abaxis, Inc. had 13 insider sales and 0 insider purchases since January 30, 2018. This’s net activity of $5.31 million. The insider EVENHUIS HENK sold $333,460. The insider SINGH PRITHIPAL sold $140,500. The insider WOOD DONALD PETER sold 10,000 shs worth $689,851. On Tuesday, May 22 1,533 shs were sold by ARON KENNETH, worth $127,408. Shares for $122,652 were sold by TOCKMAN CRAIG. On Thursday, March 8 CASEY MICHAEL D sold $355,327 worth of Abaxis, Inc. (NASDAQ:ABAX) or 5,000 shs.

Abaxis, Inc. (NASDAQ:ABAX) Ratings Coverage

In total 8 analysts cover Abaxis (NASDAQ:ABAX). “Buy” rating has 1, “Sell” are 1, while 6 are “Hold”. 13% are bullish. 11 are the (NASDAQ:ABAX)’s analyst reports since January 9, 2018 according to StockzIntelligence Inc. In Monday, January 29 report Canaccord Genuity maintained it with “Hold” rating and $65.0 target. On Tuesday, January 9 the company was upgraded by Raymond James. The company rating was upgraded by Credit Suisse on Wednesday, May 16. On Thursday, January 25 Stifel Nicolaus maintained the shares of ABAX in report with “Hold” rating. On Tuesday, January 16 the rating was maintained by Canaccord Genuity with “Hold”. In Friday, January 26 report Stephens maintained it with “Hold” rating and $60.0 target. On Monday, January 29 Northcoast maintained Abaxis, Inc. (NASDAQ:ABAX) with “Buy” rating. On Tuesday, January 9 Northcoast maintained Abaxis, Inc. (NASDAQ:ABAX) rating. Northcoast has “Buy” rating and $72.0 target. On Friday, April 27 Stifel Nicolaus maintained Abaxis, Inc. (NASDAQ:ABAX) rating. Stifel Nicolaus has “Hold” rating and $62 target. On Wednesday, May 16 the firm has “Neutral” rating given by Sidoti. Listed here are Abaxis, Inc. (NASDAQ:ABAX) PTs and latest ratings.

16/05/2018 Broker: Credit Suisse Rating: Hold Upgrade
16/05/2018 Broker: Sidoti Old Rating: Buy New Rating: Neutral Downgrade
27/04/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $57 New Target: $62 Maintain
08/02/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $46 New Target: $48 Maintain
29/01/2018 Broker: Northcoast Rating: Buy New Target: $90.0 Maintain
29/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $65.0 Maintain
26/01/2018 Broker: Stephens Rating: Hold New Target: $60.0 Maintain
25/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $57.0 Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $55.0 Maintain
09/01/2018 Broker: Northcoast Rating: Buy New Target: $72.0 Maintain

The stock increased 0.06% or $0.05 during the last trading session, touching $83.15.Abaxis, Inc. has volume of 14,333 shares. Since June 29, 2017 ABAX has risen 69.53% and is uptrending. ABAX outperformed the S&P 500 by 56.96%.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide.The firm is worth $1.90 billion. It operates in two divisions, Medical Market and Veterinary Market.71.07 is the P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

Another two news for Abaxis, Inc. (NASDAQ:ABAX) were briefly announced by: Investorplace.com on June 28, 2018 with title “7 Stocks to Buy That Aren’t in the Dow But Should Be”. The other Prnewswire.com‘s article was titled “SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Abaxis, Inc. – ABAX” and announced on June 05, 2018.

Abaxis, Inc. (NASDAQ:ABAX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.